Andarine (S-4)

• Product NameAndarine (S-4)
  CAS No.401900-40-1
  Purity99%
  Min Quantity1000Kilograms
  Price1~2
• View Contact Detail

• 
  Molecular Structure

Detailed Description

Andarine (S-4)
Synonyms: S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide;N-[4-Nitro-3-(trifluoromethyl)phenyl]-(2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methylpropanamide;Ostarine;(2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide;MK-2866;Andarine;Propanamide,3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phe nyl]-,(2S)-;sarM s4
CAS: 401900-40-1
MF: C19H18F3N3O6
MW: 441.36
Product Categories: APIs;Amines;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
Chemical Properties:Pale Yellow Solid
Assay:98%
Usage:It is a potent and tissue-selective androgen receptor modulator (SARM)
Packing:foil bag or as required

Ostarine,MK-2866, Enobosarm Enobosarm (Ostarine, MK-2866, GTx-024) - affects both muscle and bone, intended mainly for osteoporosis but also general treatment for andropause and reversing muscle sarcopenia in the elderly and for cachexia in cancer patients.
LGD-4033 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866

MK-677, Ibutamoren, a secretagogue a secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
Andarine (S-4) partial agonist, intended mainly for treatment of benign prostatic hypertrophy

GW-501516 It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease
Name CAS NO. Usage
AICAR 2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0 A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
SR9011 1379686-30-2 For obesity, diabetes, dyslipidemia and cardiovascular disease
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11 366508-78-3 YK11: a SARM and myostatin inhibitor in one
431579-34-9

• 
• Andarine (S-4)